Alignment Healthcare, Inc.
13.03USD
-0.4300 (-3.19%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.06▼ | $0.14 | 0 | 1 |
| Next quarter | $0.05▲ | $0 | 1 | 0 |
| Current year | $0.5▲ | $0.48 | 3 | 0 |
| Next year | $0.75▲ | $0.72 | 2 | 0 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.2 | $0.25 | +0.05 (+24.3%) |
| 2026-03-31 | $0.09 | $0.12 | +0.03 (+38.7%) |
| 2025-12-31 | $-0.08 | $-0 | +0.08 (+98.2%) |
| 2025-09-30 | $-0.01 | $0.1 | +0.11 (+1081.0%) |
95 ratings from 16 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Overweight | $26 $22 | Aug 4, 2026 |
| Raymond James | Downgraded from Strong Buy | Outperform | $22 $19 | Aug 3, 2026 |
| Barclays | Maintained | Equal-Weight | $19 $16 | May 26, 2026 |
| UBS | Maintained | Neutral | $21 $22 | May 1, 2026 |
| Barclays | Maintained | Equal-Weight | $18 $19 | May 1, 2026 |
| JP Morgan | Maintained | Overweight | $23 $26 | Feb 5, 2026 |
| TD Cowen | Maintained | Buy | $18.5 $25 | Jan 16, 2026 |
| UBS | Maintained | Neutral | $18 $21 | Jan 14, 2026 |
| Piper Sandler | Maintained | Overweight | $20 $30 | Jan 6, 2026 |
| JP Morgan | Maintained | Overweight | $20 $23 | Dec 17, 2025 |
| JP Morgan | Upgraded from Neutral | Overweight | $18 $20 | Nov 24, 2025 |
| JP Morgan | Maintained | Neutral | $17 $18 | Nov 5, 2025 |
| Barclays | Maintained | Equal-Weight | $13 $18 | Nov 3, 2025 |
| UBS | Maintained | Neutral | $17 $18 | Oct 31, 2025 |
| Goldman Sachs | Initiated | Buy | $21 | Oct 14, 2025 |
| Keybanc | Upgraded from Sector Weight | Overweight | $21 | Aug 25, 2025 |
| Barclays | Upgraded from Underweight | Equal-Weight | $9 $13 | Jul 31, 2025 |
| UBS | Maintained | Neutral | $16 $17 | May 2, 2025 |
| Baird | Maintained | Outperform | $17 $22 | Apr 15, 2025 |
| Stifel | Maintained | Buy | $18 $23 | Apr 8, 2025 |
| JP Morgan | Maintained | Neutral | $14 $17 | Mar 6, 2025 |
| Piper Sandler | Maintained | Overweight | $14 $21 | Mar 4, 2025 |
| B of A Securities | Maintained | Buy | $15.5 $18.5 | Mar 4, 2025 |
| Stifel | Maintained | Buy | $16 $18 | Feb 28, 2025 |
| Barclays | Maintained | Underweight | $8 $9 | Feb 28, 2025 |
153 filings from 23 insiders · 23 buy / 31 sell over 6m
Officers and directors of ALHC, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MARONEY DAWN CHRISTINEPresident | Sell | 5.0k | $14.00 | $70k | Aug 14, 2026 |
| KAO JOHNChief Executive Officer | Sellindirect | 298.0k | $13.88 | $4.14M | Aug 10, 2026 |
| MARONEY DAWN CHRISTINEPresident | Exercise | 152.1k | $9.06 | $1.38M | Jul 15, 2026 |
| MARONEY DAWN CHRISTINEPresident | Sell | 177.1k | $20.83 | $3.69M | Jul 15, 2026 |
| KAO JOHNChief Executive Officer | Sellindirect | 298.0k | $19.81 | $5.92M | Jul 10, 2026 |
| KONOWIECKI JOSEPH SOfficer and Director | Sell | 25.0k | $24.00 | $600k | Jul 1, 2026 |
| HOCHRADEL SHANE JChief Operating Officer | Grant | 87.7k | — | — | Jul 1, 2026 |
| KONOWIECKI JOSEPH SOfficer and Director | Sell | 25.0k | $23.00 | $575k | Jun 26, 2026 |
| KONOWIECKI JOSEPH SOfficer and Director | Sell | 25.0k | $22.00 | $550k | Jun 18, 2026 |
| MARONEY DAWN CHRISTINEPresident | Sell | 30.0k | $19.55 | $586k | Jun 15, 2026 |
| KIM HYONG JOfficer | Sell | 36.0k | $19.86 | $714k | Jun 12, 2026 |
| KONOWIECKI JOSEPH SOfficer and Director | Sell | 25.0k | $21.00 | $525k | Jun 11, 2026 |
| KAO JOHNChief Executive Officer | Sellindirect | 298.0k | $19.65 | $6.07M | Jun 10, 2026 |
| KONOWIECKI JOSEPH SOfficer and Director | Grant | 122.8k | — | — | Jun 3, 2026 |
| KENT MARK DPresident | Grant | 87.7k | — | — | Jun 3, 2026 |
| KENT MARK DOfficer | Buy | 14.8k | $13.31 | $198k | Jun 2, 2026 |
| MARONEY DAWN CHRISTINEPresident | Gift | 21.5k | — | — | May 18, 2026 |
| MARONEY DAWN CHRISTINEPresident | Sell | 30.0k | $16.09 | $483k | May 15, 2026 |
| KAO JOHNChief Executive Officer | Sellindirect | 298.0k | $16.85 | $5.03M | May 11, 2026 |
| MARONEY DAWN CHRISTINEPresident | Sell | 30.0k | $20.87 | $626k | Apr 15, 2026 |
No analyst notes on ALHC yet.
Analyst Ratings
13 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 9 | 2 | 0 | 0 | Buy1.93 |
| 1 mo ago | 2 | 10 | 2 | 0 | 0 | Buy2.00 |
| 2 mo ago | 2 | 10 | 2 | 0 | 0 | Buy2.00 |